Cardoso HG

Language: Spanish
References: 10
Page: 98-99
PDF size: 95.38 Kb.

Text Extraction

No abstract

REFERENCES

1. Oshitani H. Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic. J Infect Chemother 2006;12:167-71.

2. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 2002;76:105-15.

3. World Health Assembly. Strengthening pandemic-influenza preparedness and response: WHA58.5. Mayo, 2005. Internet. En línea, disponible en: http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_5-en.pdf Consultado el 12 de febrero de 2008.

4. Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med 1991;65:4-21.

5. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:441-6.

6. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006;12:55-60.

7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51.

8. WHO. Global pandemic influenza action plan to increase vaccine supply. WHO/IVB/06.13. 2006. Internet. En línea, disponible en: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_1/en/index.html Consultado el 12 de febrero de 2008.

9. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003;36:1552-61.

10. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71.